• Dimethyloxalylglycine (DMOG): Technical Parameters for Hypox

  2026-08-01

  Dimethyloxalylglycine (DMOG) is a practical tool for researchers modeling hypoxia-inducible factor stabilization and hypoxia signaling in vitro and in vivo. It is not suitable for diagnostic or therapeutic use and requires careful attention to solubility and storage parameters for reproducible results.

• Dose- and Time-Dependent Neurotoxicity of Ibotenic Acid in M

  2026-07-31

  This study delivers the first systematic in vivo analysis of ibotenic acid’s neurotoxicity in mice, demonstrating a clear dose- and time-dependent relationship. The findings identify early behavioral, biochemical, and neuronal injury markers, advancing the mechanistic understanding of neurotoxic mushroom poisoning and informing future research on neurodegenerative disease modeling.

• Gap19: Precision Connexin 43 Hemichannel Blockade in Inflamm

  2026-07-31

  Explore how Gap19, a selective connexin 43 hemichannel blocker, enables targeted modulation of neuroinflammation and neuroprotection in cerebral ischemia. This article uniquely bridges mechanistic discovery with assay design, highlighting practical considerations for translational neuroscience.

• Anagliptin (SK-0403): Translational Leverage in Diabetes & V

  2026-07-30

  This thought-leadership article explores how Anagliptin (SK-0403) redefines translational diabetes research by bridging DPP-4 inhibition with direct vasorelaxant mechanisms. Integrating mechanistic insight, protocol guidance, and strategic outlook, it positions APExBIO's Anagliptin as a research-standard for dissecting the intertwined challenges of metabolic and vascular dysfunction.

• D-Luciferin Sodium Salt: Optimizing Bioluminescence Assays i

  2026-07-30

  Discover how D-Luciferin sodium salt, the gold-standard firefly luciferase substrate, enables next-generation bioluminescence imaging for advanced immunotherapy research. This article uniquely bridges assay optimization with recent breakthroughs in CAR macrophage programming.

• Praeruptorin A: Applied Workflows for Inflammation & Oncolog

  2026-07-29

  Praeruptorin A, an angular pyranocoumarin compound, empowers researchers with advanced anti-inflammatory and ferroptosis inhibition tools across oncology, cardiomyopathy, and colitis models. This guide details robust workflows, protocol enhancements, and troubleshooting strategies that maximize translational insights with confidence.

• GPR35-KLF5 Circuitry Orchestrates Epithelial Repair in Colit

  2026-07-29

  This study reveals how intestinal epithelial cells decode mucosal damage via a tryptophan metabolic 'gatekeeping' mechanism, mediated by the GPR35-KLF5 axis. These findings clarify the cellular logic underlying epithelial repair in ulcerative colitis and inform the design of advanced murine colitis models for IBD research.

• Strategic Translational Discovery with FDA-Approved Drug Lib

  2026-07-28

  This thought-leadership article explores the mechanistic and strategic foundations for leveraging the DiscoveryProbe™ FDA-approved Drug Library in translational research. It integrates recent literature, including a dual FRET-stress granule screening system, and highlights the pivotal role of well-characterized compound collections in accelerating drug repositioning and novel target identification across oncology, neurodegenerative, and antiviral research.

• LESD-Based Tools Reveal Overlapping Caspase-1 and Caspase-8

  2026-07-28

  This study introduces novel peptide inhibitors derived from the IL-18 sequence to dissect substrate preferences among inflammatory and apoptotic caspases. The findings show that caspase-1 inhibitors such as VX-765 also exhibit cross-inhibition of caspase-8, challenging established notions of selectivity and guiding improved tool development for cell death and inflammation research.

• Fingolimod (FTY720): A New Era for In Vivo T Cell Engineerin

  2026-07-27

  Explore how Fingolimod (FTY720), a leading S1P receptor modulator, is redefining the landscape of in vivo T cell engineering for solid tumor immunotherapy. This article synthesizes mechanistic insights, practical guidance, and competitive perspectives—empowering translational researchers to navigate the next generation of precision immune modulation beyond multiple sclerosis. Discover how APExBIO’s high-purity Fingolimod is fueling this paradigm shift, with actionable protocol parameters and a forward-looking outlook on neuroimmune research.

• FGFR1 Identified as a Druggable Target in Schizophrenia Ther

  2026-07-27

  A recent comprehensive analysis integrates genetic association, Mendelian randomization, and molecular docking to identify FGFR1 as a highly promising druggable gene for schizophrenia. This mechanistic insight provides researchers with new directions for targeted schizophrenia therapy and highlights the value of multi-omics approaches.

• Estradiol Benzoate (SKU B1941): Reliable Agonist for ERα Ass

  2026-07-26

  This article addresses persistent lab challenges in hormone receptor binding and cell viability assays, demonstrating how Estradiol Benzoate (SKU B1941) delivers reproducibility and data-driven confidence for estrogen receptor alpha (ERα) research. By examining practical scenarios, we provide actionable guidance on protocol optimization, data interpretation, and product selection for scientists seeking robust, high-purity reagents.

• Mithramycin A: Applied Workflows in Cancer and Cardiac Model

  2026-07-25

  Mithramycin A stands out as a precision tool for dissecting G-C-rich DNA transcriptional networks, enabling targeted inhibition of c-myc and Sp1 in both leukemia and cardiac injury research. This guide delivers practical workflows, protocol parameters, and troubleshooting strategies to maximize the reliability and reproducibility of Mithramycin A-based assays.

• Mouse Tissue Lysis Kit (K1038): Technical Usage and Workflow

  2026-07-24

  The Mouse Tissue Lysis Kit (K1038) addresses the need for rapid and simplified lysis of mouse tissues for direct PCR-based genotyping and DNA analysis in molecular biology research. It is not suitable for diagnostic or medical purposes and should be used strictly within established research workflows.

• Trelagliptin Succinate Restores Chondrocyte Function via AMP

  2026-07-24

  The referenced study uncovers a novel anti-inflammatory effect of Trelagliptin succinate (SYR-472 succinate): it restores chondrocyte function impaired by IL-1β by activating the AMPK/SOX-9 pathway. These findings expand the relevance of this DPP-4 inhibitor beyond type 2 diabetes research, suggesting potential applications in osteoarthritis and inflammation-driven cartilage degeneration.

460 records 10/31 page Previous Next First page 上5页 678910 下5页 Last page